<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637182</url>
  </required_header>
  <id_info>
    <org_study_id>1033US/0016</org_study_id>
    <secondary_id>D5394L00016</secondary_id>
    <nct_id>NCT00637182</nct_id>
  </id_info>
  <brief_title>Gynecomastia Extension Study</brief_title>
  <official_title>An OptioExtension of Trial 1033US/0006 to Assess Safety, Tolerability, Efficacy of Anastrozole (ZD1033, Arimidex™) in Treatment of Gynecomastia in Pubertal Boys Given Placebo and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in
      reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another
      anastrozole study).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in linear dimensions of the breast</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in breast tenderness</measure>
  </secondary_outcome>
  <condition>Gynecomastia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <other_name>ZD1033</other_name>
    <other_name>Arimidex™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have entered Trial 1033US/0006 and completed 6 months of treatment and
             one month of follow-up.

          -  Subjects must have gynecomastia, with one breast measuring at least 3 cm in diameter.

        Exclusion Criteria:

          -  Subjects who have been given medications known to cause gynecomastia within the
             previous 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward O Reiter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baystate Medical Center-Children's Hospital</affiliation>
  </overall_official>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>March 10, 2008</last_update_submitted>
  <last_update_submitted_qc>March 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Francisco Sapunar - Medical Science Director</name_title>
    <organization>Arimidex</organization>
  </responsible_party>
  <keyword>Gynecomastia</keyword>
  <keyword>Anastrazole</keyword>
  <keyword>Arimidex</keyword>
  <keyword>Pubertal</keyword>
  <keyword>males</keyword>
  <keyword>boys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gynecomastia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

